CORRECTION - Financial agenda for 2025

Villepinte, 13 janvier 2025: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2025.

Publications calendar
  • 2024 ANNUAL REVENUE
February 06, 2025, after trading
  • 2024 ANNUAL RESULTS
March 26, 2025, after trading
  • 2025 1st QUARTER REVENUE
April 24, 2025, after trading
  • ANNUAL SHAREHOLDERS' MEETING
May 23, 2025
  • 2025 2nd QUARTER REVENUE
July 24, 2025, after trading
  • 2025 FIRST HALF RESULTS
September 24, 2025, after trading
  • 2025 3rd QUARTER REVENUE
October 23, 2025, after trading
About Guerbet

At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 95 years, with more than 2,600 employees worldwide, we continuously innovate and devote 10% of our sales to research and development in four centres in France, in United States and Israël. Guerbet (GBT) is listed on Euronext Paris (segment B - mid caps) and generated €786 million in revenue in 2023.

 

Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

 

Contacts:

Guerbet     

Jérôme Estampes, Chief Financial Officer + 33 1 45 91 50 00 / [email protected] 

Christine Allard, Head of Public Affairs and Communications: +33 6 30 11 57 82 / [email protected]

Seitosei.Actifin                                                                                       

Marianne Py, Financial Communication + 33 1 80 48 25 31 / [email protected]

Jennifer Jullia, Press +33 1 56 88 11 19 / [email protected]

Attachment